Mr 2097-CL | CAS#62767-48-0

MedKoo Cat#: 534670 | Name: Mr 2097-CL

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Mr 2097-CL is a bioactive chemical.

Chemical Structure

Mr 2097-CL

CAS#62767-48-0

Theoretical Analysis

MedKoo Cat#: 534670

Name: Mr 2097-CL

CAS#: 62767-48-0

Chemical Formula: C21H26ClNO5

Exact Mass: 407.1500

Molecular Weight: 407.89

Elemental Analysis: C, 61.84; H, 6.43; Cl, 8.69; N, 3.43; O, 19.61

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Mr 2097-CL; Mr2097-CL; Mr-2097-CL

IUPAC/Chemical Name

Morphinan-6-one, 4,5-epoxy-3,14-dihydroxy-17-((tetrahydro-2-furanyl)methyl)-, hydrochloride, (5-alpha,17(S))-

InChi Key

VSSSUJQGBBHOLO-UDPUCJLXSA-N

InChi Code

InChI=1S/C21H25NO5.ClH/c23-14-4-3-12-10-16-21(25)6-5-15(24)19-20(21,17(12)18(14)27-19)7-8-22(16)11-13-2-1-9-26-13;/h3-4,13,16,19,23,25H,1-2,5-11H2;1H/t13?,16-,19+,20+,21-;/m1./s1

SMILES Code

O=C1[C@@]2([H])[C@]34C5=C(O2)C(O)=CC=C5C[C@@H](N(CC6OCCC6)CC4)[C@]3(O)CC1.[H]Cl

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 407.89 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Boisot T. Ben. Ment Retard. 2000 Aug;38(4):375-7. doi: 10.1352/0047-6765(2000)038<0375:B>2.0.CO;2. PMID: 10981201. 2: Beedle AM. Distribution of myosin heavy chain isoforms in muscular dystrophy: insights into disease pathology. Musculoskelet Regen. 2016;2:e1365. Epub 2016 Jul 5. PMID: 27430020; PMCID: PMC4943764. 3: Fang F, Wei X, Hu M, Liu F. A mouse model of craniofacial bone lesion of tuberous sclerosis complex. Musculoskelet Regen. 2015;1(1):e814. doi: 10.14800/mr.814. PMID: 26052552; PMCID: PMC4456023. 4: Perske R. Unlikely heroes. Ment Retard. 2005 Oct;43(5):369-75. doi: 10.1352/0047-6765(2005)43[369:UH]2.0.CO;2. PMID: 16131236. 5: Berkson G. Intellectual and physical disabilities in prehistory and early civilization. Ment Retard. 2004 Jun;42(3):195-208. doi: 10.1352/0047-6765(2004)42<195:IAPDIP>2.0.CO;2. PMID: 15117226. 6: McMillan E. A parent's perspective. Ment Retard. 2005 Oct;43(5):351-3. doi: 10.1352/0047-6765(2005)43[351:APP]2.0.CO;2. PMID: 16131232. 7: Vehmas S. Ethical analysis of the concept of disability. Ment Retard. 2004 Jun;42(3):209-22. doi: 10.1352/0047-6765(2004)42<209:EAOTCO>2.0.CO;2. PMID: 15117225. 8: Jobling A. Beyond sex and cooking: health education for individuals with intellectual disability. Ment Retard. 2001 Aug;39(4):310-21. doi: 10.1352/0047-6765(2001)039<0310:BSACHE>2.0.CO;2. PMID: 11448253. 9: Walsh KK, Kastner TA, Green RG. Cost comparisons of community and institutional residential settings: historical review of selected research. Ment Retard. 2003 Apr;41(2):103-22. doi: 10.1352/0047-6765(2003)041<0103:CCOCAI>2.0.CO;2. PMID: 12622527. 10: Tachibana T, Watanabe K. Japanese studies on attitudes towards persons with mental retardation. Ment Retard. 2002 Jun;40(3):245-51. doi: 10.1352/0047-6765(2002)040<0245:jsoatp>2.0.co;2. PMID: 22509518. 11: Doran SM, Harvey MT, Horner RH. Sleep and developmental disabilities: assessment, treatment, and outcome measures. Ment Retard. 2006 Feb;44(1):13-27. doi: 10.1352/0047-6765(2006)44[13:SADDAT]2.0.CO;2. PMID: 16405384. 12: Butler FM, Miller SP, Lee KH, Pierce T. Teaching mathematics to students with mild-to-moderate mental retardation: a review of the literature. Ment Retard. 2001 Feb;39(1):20-31. doi: 10.1352/0047-6765(2001)039<0020:TMTSWM>2.0.CO;2. PMID: 11270211. 13: Holburn S, Vietze P. Acknowledging barriers in adopting person-centered planning. Ment Retard. 1999 Apr;37(2):117-24. doi: 10.1352/0047-6765(1999)037<0117:ABIAPP>2.0.CO;2. PMID: 10337128. 14: Hayden MF, Kim SH, DePaepe P. Health status, utilization patterns, and outcomes of persons with intellectual disabilities: review of the literature. Ment Retard. 2005 Jun;43(3):175-95. doi: 10.1352/0047-6765(2005)43[175:HSUPAO]2.0.CO;2. PMID: 15882081. 15: Waldman HB, Perlman SP. Mandating education of dental graduates to provide care to individuals with intellectual and developmental disabilities. Ment Retard. 2006 Jun;44(3):184-8. doi: 10.1352/0047-6765(2006)44[184:MEODGT]2.0.CO;2. PMID: 16677063.